Oral News and Research

RSS

Phase I clinical trial of DFMO initiated to treat children with neuroblastoma

A new Phase I clinical trial sponsored by the Vermont Cancer Center at the University of Vermont and Fletcher Allen Health Care has opened to test the investigational drug DFMO, or alpha-difluoromethylornithine, as a treatment for the pediatric cancer neuroblastoma.

15 Apr 2010

Potential new drug for treatment of MS to be presented at AAN Annual Meeting

Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology Annual Meeting, including a potential new drug for the treatment of multiple sclerosis and surprising trends showing a reduction in the disease's severity. The meeting will take place April 10-17 in Toronto.

15 Apr 2010

John Muir Physician Network to participate in Generex Oral-lyn FDA Expanded Access Treatment IND program

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that John Muir Physician Network Clinical Research Center has agreed to participate in the United States Food and Drug Administration (FDA) Expanded Access Treatment Investigational New Drug (IND) Program for the Company's flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product.

15 Apr 2010

CDHP applauds dental coverage in health care reform legislation

The Children's Dental Health Project (CDHP) today applauded the historic dental health care provisions that were recently enacted as part of the health care reform legislation signed into law by President Obama. The provisions contained in the legislation represent an unprecedented investment in the oral health of all Americans, especially children.

15 Apr 2010

M2010 to encompass broader spectrum of HIV prevention research

HIV prevention researchers, policy makers and community advocates from more than 35 countries will be in Pittsburgh, May 22-25 to attend the 2010 International Microbicides Conference.

15 Apr 2010

Toothpaste with triclosan/copolymer kills harmful germs

The human mouth is home to an estimated 800 to 1,000 different kinds of bacteria. The warm and moist environment, along with hard tooth surfaces and soft tissues, prove to be optimal factors in boosting germ growth. Many of these bacteria are harmful and can form a film on teeth called "dental plaque," which causes cavities, gingivitis and eventually more severe kinds of gum disease.

15 Apr 2010

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.

15 Apr 2010

SCL provides affordable orthodontic program for children

You've done your taxes and 2009 proved to be a pretty bad year. Your tax return shows just how much less money your family earned, making the possibility of providing orthodontic treatment for your children this year even more distant.

15 Apr 2010

New AIGISRx Flat provides antimicrobial protection from CRMD infection

TYRX, Inc. announced today the commercial release of the AIGISRx™ Flat, an antibacterial product that helps provide protection against infections associated with implanted pacemakers and defibrillators.

15 Apr 2010

Drinking tap water is a cost-effective way to fight tooth decay

Tooth decay affects children in the United States more than any other chronic infectious disease, according to the Centers for Disease Control and Prevention (CDC). The CDC states that tooth decay, if left untreated, can cause pain and infections that hinder eating, speaking, playing and learning.

15 Apr 2010

AACR Annual Meeting 2010: Æterna Zentaris to present data on Erk/PI3K inhibitor compounds

Æterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it will make an oral presentation, as well as a poster presentation on Erk/PI3K inhibitor compounds, Tuesday, April 20, at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 17-21, 2010 at the Walter E. Washington Convention Center in Washington, D.C.

13 Apr 2010

EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.

13 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer, today announced the upcoming presentations of clinical data from the company's two lead programs, VB-201 and VB-111, at premier dermatology and cancer research medical meetings this spring.

13 Apr 2010

Delcath's Phase III PHP-mel trial data accepted for presentation at ASCO's 2010 Annual Meeting

Delcath Systems, Inc., a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today that the American Society of Clinical Oncology (ASCO) has accepted an abstract for oral presentation of Delcath's Phase III Trial Data comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma for ASCO's 2010 Annual Meeting, to be held June 4-8, 2010 at McCormick Place in Chicago.

13 Apr 2010

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Myriad Pharmaceuticals, Inc today announced that it has received a notice from Javelin Pharmaceuticals, Inc. of its intent to terminate the merger agreement between the two companies.

13 Apr 2010

Vitamins touted in skin care products reduce signs of sun-damaged skin: Study

While everyone knows that getting an adequate daily dose of vitamins and minerals is important in maintaining one's overall health, many question whether or not the vitamins touted in skin care products work in reducing the signs of sun-damaged skin.

13 Apr 2010

Oragenics signs distribution agreement with RICCI PHARMA

Florida-based biotechnology company Oragenics, Inc., and RICCI PHARMA, a recognized health products company with offices in Rome and Slovakia, have entered into a distribution agreement that the parties anticipate will provide Oragenics' proprietary oral care probiotic products, EvoraPlus® and EvoraKidsTM, to RICCI PHARMA. RICCI PHARMA will have exclusive distribution rights through Duc in Altum, a foundation whose humanitarian projects are inspired by the social teachings of the late Pope John Paul II.

13 Apr 2010

Increase in circulating stem cells can be achieved through Stem-Kine: Study

A study published in the peer reviewed Journal of Translational Medicine demonstrated administration of Stem-Kine, a commercially available nutritional supplement, significantly elevated levels of two types of stem cells in circulation.

13 Apr 2010

Elastomers speed regulatory compliance of speech therapy devices, enhance toughness

A supplier of tools to aid in speech therapy has switched from conventional thermoplastic elastomers to Medalist® medical elastomers from Teknor Apex Company, citing advantages in compound selection, blending, molding, and resistance to chewing and other rugged treatment.

12 Apr 2010

Oral News and Research

Phase I clinical trial of DFMO initiated to treat children with neuroblastoma

Potential new drug for treatment of MS to be presented at AAN Annual Meeting

John Muir Physician Network to participate in Generex Oral-lyn FDA Expanded Access Treatment IND program

CDHP applauds dental coverage in health care reform legislation

M2010 to encompass broader spectrum of HIV prevention research

Toothpaste with triclosan/copolymer kills harmful germs

Combivent Inhalation Aerosol's "essential use" status effective through 2013

SCL provides affordable orthodontic program for children

New AIGISRx Flat provides antimicrobial protection from CRMD infection

Drinking tap water is a cost-effective way to fight tooth decay

AACR Annual Meeting 2010: Æterna Zentaris to present data on Erk/PI3K inhibitor compounds

EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings

Delcath's Phase III PHP-mel trial data accepted for presentation at ASCO's 2010 Annual Meeting

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Vitamins touted in skin care products reduce signs of sun-damaged skin: Study

Oragenics signs distribution agreement with RICCI PHARMA

Increase in circulating stem cells can be achieved through Stem-Kine: Study

Elastomers speed regulatory compliance of speech therapy devices, enhance toughness

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News